267
Views
14
CrossRef citations to date
0
Altmetric
Reviews

Janus kinase 2 inhibitors in myeloproliferative disorders

, , , , , , , , , , , , , , & show all
Pages 41-59 | Published online: 04 Dec 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Brian L Harry, S. Gail Eckhardt & Antonio Jimeno. (2012) JAK2 inhibition for the treatment of hematologic and solid malignancies. Expert Opinion on Investigational Drugs 21:5, pages 637-655.
Read now

Articles from other publishers (13)

J. Lemaire, A. Rosière, C. Bertrand, B. Bihin, J. E. Donckier & L. A. Michel. (2017) Surgery for massive splenomegaly. BJS Open 1:1, pages 11-17.
Crossref
Maria Gabriella Brasca, Paola Gnocchi, Marcella Nesi, Nadia Amboldi, Nilla Avanzi, Jay Bertrand, Simona Bindi, Giulia Canevari, Daniele Casero, Marina Ciomei, Nicoletta Colombo, Sabrina Cribioli, Gabriele Fachin, Eduard R. Felder, Arturo Galvani, Antonella Isacchi, Ilaria Motto, Achille Panzeri & Daniele Donati. (2015) Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders. Bioorganic & Medicinal Chemistry 23:10, pages 2387-2407.
Crossref
Maria Gabriella Brasca, Marcella Nesi, Nilla Avanzi, Dario Ballinari, Tiziano Bandiera, Jay Bertrand, Simona Bindi, Giulia Canevari, Davide Carenzi, Daniele Casero, Lucio Ceriani, Marina Ciomei, Alessandra Cirla, Maristella Colombo, Sabrina Cribioli, Cinzia Cristiani, Franco Della Vedova, Gabriele Fachin, Marina Fasolini, Eduard R. Felder, Arturo Galvani, Antonella Isacchi, Danilo Mirizzi, Ilaria Motto, Achille Panzeri, Enrico Pesenti, Paola Vianello, Paola Gnocchi & Daniele Donati. (2014) Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors. Bioorganic & Medicinal Chemistry 22:17, pages 4998-5012.
Crossref
Qibin Su, Stephanos Ioannidis, Claudio Chuaqui, Lynsie Almeida, Marat Alimzhanov, Geraldine Bebernitz, Kirsten Bell, Michael Block, Tina Howard, Shan Huang, Dennis Huszar, Jon A. Read, Caroline Rivard Costa, Jie Shi, Mei Su, Minwei Ye & Michael Zinda. (2013) Discovery of 1-Methyl-1 H -imidazole Derivatives as Potent Jak2 Inhibitors . Journal of Medicinal Chemistry 57:1, pages 144-158.
Crossref
Michael Siu, Richard Pastor, Wendy Liu, Kathy Barrett, Megan Berry, Wade S. Blair, Christine Chang, Jacob Z. Chen, Charles Eigenbrot, Nico Ghilardi, Paul Gibbons, Haiying He, Christopher A. Hurley, Jane R. Kenny, S. Cyrus Khojasteh, Hoa Le, Leslie Lee, Joseph P. Lyssikatos, Steve Magnuson, Rebecca Pulk, Vickie Tsui, Mark Ultsch, Yisong Xiao, Bing-yan Zhu & Deepak Sampath. (2013) 2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors. Bioorganic & Medicinal Chemistry Letters 23:17, pages 5014-5021.
Crossref
Xiaoyun Wu, Shanhe Wan & Jiajie Zhang. (2013) Three Dimensional Quantitative Structure-Activity Relationship of 5H-Pyrido[4,3-b]indol-4-carboxamide JAK2 Inhibitors. International Journal of Molecular Sciences 14:6, pages 12037-12053.
Crossref
Hans C. Hasselbalch. (2013) The role of cytokines in the initiation and progression of myelofibrosis. Cytokine & Growth Factor Reviews 24:2, pages 133-145.
Crossref
Hun Ju Lee, Naval Daver, Hagop M. Kantarjian, Srdan Verstovsek & Farhad Ravandi. (2013) The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clinical Cancer Research 19:2, pages 327-335.
Crossref
Janusz J. Kulagowski, Wade Blair, Richard J. Bull, Christine Chang, Gauri Deshmukh, Hazel J. Dyke, Charles Eigenbrot, Nico Ghilardi, Paul Gibbons, Trevor K. Harrison, Peter R. Hewitt, Marya Liimatta, Christopher A. Hurley, Adam Johnson, Tony Johnson, Jane R. Kenny, Pawan Bir Kohli, Robert J. Maxey, Rohan Mendonca, Kyle Mortara, Jeremy Murray, Raman Narukulla, Steven Shia, Micah Steffek, Savita Ubhayakar, Mark Ultsch, Anne van Abbema, Stuart I. Ward, Bohdan Waszkowycz & Mark Zak. (2012) Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors. Journal of Medicinal Chemistry 55:12, pages 5901-5921.
Crossref
Brendan D. Looyenga, Danielle Hutchings, Irene Cherni, Chris Kingsley, Glen J. Weiss & Jeffrey P. MacKeigan. (2012) STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma. PLoS ONE 7:2, pages e30820.
Crossref
David Mitchell, Kevin P. Cole, Patrick M. Pollock, David M. Coppert, Timothy P. Burkholder & Joshua R. Clayton. (2011) Development and a Practical Synthesis of the JAK2 Inhibitor LY2784544. Organic Process Research & Development 16:1, pages 70-81.
Crossref
Jongwon Lim, Brandon Taoka, Ryan D. Otte, Kerrie Spencer, Christopher J. Dinsmore, Michael D. Altman, Grace Chan, Craig Rosenstein, Sujata Sharma, Hua-Poo Su, Alexander A. Szewczak, Lin Xu, Hong Yin, Joan Zugay-Murphy, C. Gary Marshall & Jonathan R. Young. (2011) Discovery of 1-Amino-5 H -pyrido[4,3- b ]indol-4-carboxamide Inhibitors of Janus Kinase 2 (JAK2) for the Treatment of Myeloproliferative Disorders . Journal of Medicinal Chemistry 54:20, pages 7334-7349.
Crossref
Rodrigo Lopes da Silva, Patricia Ribeiro, Alexandra Lourenço, Susana Costa Santos, Margarida Santos, Isabel Costa & Aida Botelho de Sousa. (2011) What Is the Role of JAK2<sup>V617F</sup> Mutation in Leukemic Transformation of Myeloproliferative Neoplasms?. Laboratory Hematology 17:1, pages 12-16.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.